Michael Stanglmaier

532 total citations
9 papers, 418 citations indexed

About

Michael Stanglmaier is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Michael Stanglmaier has authored 9 papers receiving a total of 418 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 5 papers in Pathology and Forensic Medicine and 5 papers in Oncology. Recurrent topics in Michael Stanglmaier's work include Chronic Lymphocytic Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and CAR-T cell therapy research (4 papers). Michael Stanglmaier is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and CAR-T cell therapy research (4 papers). Michael Stanglmaier collaborates with scholars based in Germany and United States. Michael Stanglmaier's co-authors include Michael Hallek, Horst Lindhofer, Markus Warmuth, Raymund Buhmann, Peter Ruf, Matt Dunn, Silke U. Reiffert, Robert Rauchenberger, Benno Rattel and Mark Wing and has published in prestigious journals such as Nature Medicine, International Journal of Cancer and Gene.

In The Last Decade

Michael Stanglmaier

9 papers receiving 403 citations

Peers

Michael Stanglmaier

IMMUN

RNMI

ONCOL

GENET

MB

JR Kalden Germany

H Mellstedt Sweden

Shui‐on Leung United States

S Kiesel Germany

Kenneth A. Foon United States

Nadine Kutsch Germany

Eva Hug Germany

John A. Majda United States

AC Fluckiger Israel

Chisako Iriyama Japan

JR Kalden Germany

Michael Stanglmaier

226 ×1.2

IMMUN

119 ×0.7

RNMI

72 ×0.5

ONCOL

44 ×0.4

GENET

94 ×0.8

MB

Citations per year, relative to Michael Stanglmaier Michael Stanglmaier (= 1×) peers JR Kalden

Countries citing papers authored by Michael Stanglmaier

Since Specialization

Citations

This map shows the geographic impact of Michael Stanglmaier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Stanglmaier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Stanglmaier more than expected).

Fields of papers citing papers by Michael Stanglmaier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Stanglmaier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Stanglmaier. The network helps show where Michael Stanglmaier may publish in the future.

Co-authorship network of co-authors of Michael Stanglmaier

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Stanglmaier. A scholar is included among the top collaborators of Michael Stanglmaier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Stanglmaier. Michael Stanglmaier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Schuster, Friedhelm R., Michael Stanglmaier, Wilhelm Woessmann, et al.. (2014). Immunotherapy with the trifunctional anti‐CD20 x anti‐CD3 antibody FBTA05 (Lymphomun) in paediatric high‐risk patients with recurrent CD20‐positive B cell malignancies. British Journal of Haematology. 169(1). 90–102. 25 indexed citations

2.

Buhmann, Raymund, Michael Stanglmaier, Juergen Heß, et al.. (2013). Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. Journal of Translational Medicine. 11(1). 160–160. 27 indexed citations

3.

Buhmann, Raymund, Michael Stanglmaier, Juergen Heß, et al.. (2013). Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven,. 11. 160. 3 indexed citations

4.

Buhmann, Raymund, Belinda Pinto Simões, Michael Stanglmaier, et al.. (2008). Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplantation. 43(5). 383–397. 33 indexed citations

5.

Stanglmaier, Michael, et al.. (2008). Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti‐CD20 × anti‐CD3), mediates efficient killing of B‐cell lymphoma cells even with very low CD20 expression levels. International Journal of Cancer. 123(5). 1181–1189. 53 indexed citations

6.

Stanglmaier, Michael, et al.. (2004). Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Annals of Hematology. 83(10). 634–45. 96 indexed citations

7.

Stanglmaier, Michael, et al.. (2003). The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia. 17(2). 283–289. 55 indexed citations

8.

Nagy, Zoltan A., Bernd Hubner, Robert Rauchenberger, et al.. (2002). Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nature Medicine. 8(8). 801–807. 122 indexed citations

9.

Stanglmaier, Michael & Ernst‐Ludwig Winnacker. (1996). Cloning, sequence determination and functional expression of the genes encoding adenovirus type-4 polymerase and the terminal protein precursor. Gene. 168(2). 177–182. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact